Clinical trial · Observational
Study of the Predictive and Prognostic Role of Pharmacogenetic and Radiogenic Variants on the Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In locally advanced rectal cancer the pathological complete response (pCR) to neoadjuvant chemoradiation therapy (nCRT) is associated with a favourable long-term prognosis. The identification of markers predictive of response to therapy would therefore optimise treatment by allowing personalised therapy. It has been shown that the genetic profile of the patient could influence the activation of the immune system in combination with chemoradiation therapy in targeting tumour cells. In addition, genetic features of molecular pathways correlated with response to chemoradiotherapy, may in turn affect the probability of a good response to treatment in these patients, but also the occurrence of adverse events. The main objective of the study is to define the role of genetic markers related to immune system activation and other molecular pathways in predicting the complete pathological response to preoperative chemoradiation therapy in patients with locally advanced rectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Defining the predictive role of rare (MAF<1%) and very rare genetic variants (MAF<0.1%) in the SMAD3 and IL-17F genes, implicated in nCRT-mediated activation of the immune system on the pathological tumour response to nCRT in LARC.
- timeFrame
- up to 5 years
- description
- Relation between rare and very rare genetic variants and pathological tumour response will be assessed with logistic regression analysis and data will be reported as odds ratio and relative confidence interval
Secondary outcomes (7)
- measure
- Plasma levels of IL-17F and SMAD3 proteins during treatment to be correlated with the genetic characteristics
- timeFrame
- up to 5 years
- description
- Mean difference between subgroup of patients with different genetics characteristics
- measure
- Plasma levels of IL-17F and SMAD3 proteins during treatment and tumour response
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Eligibility criteria: 1. histologically confirmed diagnosis of primary resectable LARC; 2. confirmed absence of distant metastases; 3. ≥18 years old; 4. stage of disease T3-T4 and N0-N2; 5. performance status (World Health Organisation) 0-2; 6. normal bone marrow, kidney and liver function; Exclusion Criteria: 1. evidence of secondary tumour 2. inadequate liver function (bilirubin \>1.5 times the normal range, ALT and AST \>2 times the normal range); 3. inadequate renal function (creatinine \>1.5 times the upper limit of normal range); 4. Major concomitant systemic diseases that contraindicate surgery; 5. significant cardiovascular disease (heart failure, acute myocardial infarction within the last year, active angina, cardiac arrhythmia to be treated, uncontrolled hypertension) 6. systemic disease contraindicating radiotherapy
References
Publications (0)
Data not yet available